UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A phase II trial of pralatrexate (P) plus oxaliplatin (O) in advanced esophagogastric cancer (aEGC)

Journal of clinical oncology, 2015, Vol.33 (3_suppl), p.152-152

2015

Volltextzugriff (PDF)

Preclinical evaluation of the anti-tumor activity of pralatrexate in high-risk neuroblastoma cells

Oncotarget, 2020-08, Vol.11 (32), p.3069-3077

2020

Volltextzugriff (PDF)

Outcome in patients with peripheral T-cell lymphoma treated with pralatrexate, single center experience

Turkish journal of internal medicine (Online), 2022-01, Vol.4 (1), p.20-24

2022

Volltextzugriff (PDF)

The survival outcome of patients with relapsed/refractory peripheral T‐cell lymphoma‐not otherwise specified and angioimmunoblastic T‐cell lymphoma

British journal of haematology, 2017-03, Vol.176 (5), p.750-758

2017

Volltextzugriff (PDF)

Novel 1,3,4-Thiadiazole Linked Amide Derivatives of Pteridone: Synthesis and Study of Anticancer Activities

Letters in organic chemistry, 2020-01, Vol.17 (1), p.54-60

2020

Volltextzugriff (PDF)

Three efficient chemometrics assisted fluorimetric detection methods for interference-free, rapid, and simultaneous determination of ibrutinib and pralatrexate in various complicated biological fluids

Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2021-05, Vol.252, p.119419, Article 119419

2021

Volltextzugriff (PDF)

The Antifolates

Hematology/oncology clinics of North America, 2012-06, Vol.26 (3), p.629-648

2012

Volltextzugriff (PDF)

Pralatrexate inhibited the replication of varicella zoster virus and vesicular stomatitis virus: An old dog with new tricks

Antiviral research, 2024-01, Vol.221, p.105787-105787, Article 105787

2024

Volltextzugriff (PDF)

Pralatrexate Sustainably Released from Polypeptide Thermogel Is Effective for Chondrogenic Differentiation of Mesenchymal Stem Cells

ACS applied materials & interfaces, 2022-01, Vol.14 (3), p.3773-3783

2022

Volltextzugriff (PDF)

T time: Emerging and new therapies for peripheral T-cell lymphoma

Blood reviews, 2022-03, Vol.52, p.100889-100889, Article 100889

2022

Volltextzugriff (PDF)

Pralatrexate mediates effective killing of gemcitabine-resistant pancreatic cancer: role of mTOR/4E-BP1 signal pathway

Heliyon, 2022-12, Vol.8 (12), p.e12064-e12064, Article e12064

2022

Volltextzugriff (PDF)

Effect of leucovorin administration on mucositis and skin reactions in patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma treated with pralatrexate

Leukemia & lymphoma, 2019-10, Vol.60 (12), p.2927-2930

2019

Volltextzugriff (PDF)

Generation of pralatrexate resistant T‐cell lymphoma lines reveals two patterns of acquired drug resistance that is overcome with epigenetic modifiers

Genes chromosomes & cancer, 2020-11, Vol.59 (11), p.639-651

2020

Volltextzugriff (PDF)

Peripheral T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease

Cancer treatment reviews, 2017-11, Vol.60, p.120-129

2017

Volltextzugriff (PDF)

Advances in the pharmacotherapeutic options for primary nodal peripheral T-cell lymphoma

Expert opinion on pharmacotherapy, 2021-06, Vol.22 (9), p.1203-1215

2021

Volltextzugriff (PDF)

Deoxycholate-TPGS mixed nanomicelles for encapsulation of methotrexate with enhanced in vitro cytotoxicity on breast cancer cell lines

Journal of drug delivery science and technology, 2019-04, Vol.50, p.293-304

2019

Volltextzugriff (PDF)

Clinical Activity of Pralatrexate in Patients With Cutaneous T-Cell Lymphoma Treated With Varying Doses of Pralatrexate

Clinical lymphoma, myeloma and leukemia, 2018-11, Vol.18 (11), p.e445-e447

2018

Volltextzugriff (PDF)

Case Study: T-Cell Lymphoma

Clinical lymphoma, myeloma and leukemia, 2017-09, Vol.17, p.S168-S169

Oki, Yasuhiro

2017

Volltextzugriff (PDF)

Small Primary Cutaneous γδT-Cell Lymphoma Lesions Successfully Treated With Pralatrexate

Clinical nuclear medicine, 2019-02, Vol.44 (2), p.e85-e86

2019

Volltextzugriff (PDF)

Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum‐sensitive ovarian, fallopian tube, or primary peritoneal cancer

Cancer, 2016-11, Vol.122 (21), p.3297-3306

2016

Volltextzugriff (PDF)

Predictive model for treatment outcomes of peripheral T-cell lymphoma, not otherwise specified, in Taiwanese patients

Journal of the Formosan Medical Association, 2024-02, Vol.123 (2), p.188-197

2024

Volltextzugriff (PDF)

Characterization of newly established Pralatrexate-resistant cell lines and the mechanisms of resistance

BMC cancer, 2021-07, Vol.21 (1), p.1-879, Article 879

2021

Volltextzugriff (PDF)

Efficacy and safety of single-agent pralatrexate for treatment of angioimmunoblastic T-cell lymphoma after failure of first line therapy: a pooled analysis

Leukemia & lymphoma, 2020-07, Vol.61 (9), p.2145-2152

2020

Volltextzugriff (PDF)

Cutaneous T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease

Cancer treatment reviews, 2017-12, Vol.61, p.61-69

2017

Volltextzugriff (PDF)

Alemtuzumab is an effective third-line treatment versus single-agent gemcitabine or pralatrexate for refractory Sézary syndrome: a systematic review

EJD. European journal of dermatology, 2018-11, Vol.28 (6), p.764-774

2018

Volltextzugriff (PDF)

1 – 25 von 122

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(104)
Mit Volltextzugriff
(85)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Pralatrexate
(120)
Science & Technology
(97)
Life Sciences & Biomedicine
(92)
Humans
(68)
Oncology
(55)
Aminopterin - Analogs & Derivatives
(46)
Peripheral T-Cell Lymphoma
(28)
Hematology
(25)
Pharmacology & Pharmacy
(25)
Aminopterin - Therapeutic Use
(24)
Lymphoma
(23)
Lymphoma, T-Cell, Peripheral - Drug Therapy
(22)
Romidepsin
(21)
Male
(20)
Aged
(19)
Female
(19)
T-Cell Lymphoma
(19)
Antineoplastic Agents - Therapeutic Use
(18)
Chemotherapy
(18)
Folic Acid Antagonists - Therapeutic Use
(17)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A phase II trial of pralatrexate (P) plus oxaliplatin (O) in advanced esophagogastric cancer (aEGC)

Preclinical evaluation of the anti-tumor activity of pralatrexate in high-risk neuroblastoma cells

Outcome in patients with peripheral T-cell lymphoma treated with pralatrexate, single center experience

The survival outcome of patients with relapsed/refractory peripheral T‐cell lymphoma‐not otherwise specified and angioimmunoblastic T‐cell lymphoma

Novel 1,3,4-Thiadiazole Linked Amide Derivatives of Pteridone: Synthesis and Study of Anticancer Activities

Three efficient chemometrics assisted fluorimetric detection methods for interference-free, rapid, and simultaneous determination of ibrutinib and pralatrexate in various complicated biological fluids

The Antifolates

Pralatrexate inhibited the replication of varicella zoster virus and vesicular stomatitis virus: An old dog with new tricks

Pralatrexate Sustainably Released from Polypeptide Thermogel Is Effective for Chondrogenic Differentiation of Mesenchymal Stem Cells

T time: Emerging and new therapies for peripheral T-cell lymphoma

Pralatrexate mediates effective killing of gemcitabine-resistant pancreatic cancer: role of mTOR/4E-BP1 signal pathway

Effect of leucovorin administration on mucositis and skin reactions in patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma treated with pralatrexate

Generation of pralatrexate resistant T‐cell lymphoma lines reveals two patterns of acquired drug resistance that is overcome with epigenetic modifiers

Peripheral T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease

Advances in the pharmacotherapeutic options for primary nodal peripheral T-cell lymphoma

Deoxycholate-TPGS mixed nanomicelles for encapsulation of methotrexate with enhanced in vitro cytotoxicity on breast cancer cell lines

Clinical Activity of Pralatrexate in Patients With Cutaneous T-Cell Lymphoma Treated With Varying Doses of Pralatrexate

Case Study: T-Cell Lymphoma

Small Primary Cutaneous γδT-Cell Lymphoma Lesions Successfully Treated With Pralatrexate

Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum‐sensitive ovarian, fallopian tube, or primary peritoneal cancer

Predictive model for treatment outcomes of peripheral T-cell lymphoma, not otherwise specified, in Taiwanese patients

Characterization of newly established Pralatrexate-resistant cell lines and the mechanisms of resistance

Efficacy and safety of single-agent pralatrexate for treatment of angioimmunoblastic T-cell lymphoma after failure of first line therapy: a pooled analysis

Cutaneous T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease

Alemtuzumab is an effective third-line treatment versus single-agent gemcitabine or pralatrexate for refractory Sézary syndrome: a systematic review

Suchergebnisse filtern